Arrowhead Pharmaceuticals, Inc. (ARWR)
NASDAQ: ARWR · Real-Time Price · USD
19.93
+0.01 (0.05%)
Oct 24, 2024, 4:00 PM EDT - Market closed
Arrowhead Pharmaceuticals Employees
Arrowhead Pharmaceuticals had 525 employees as of September 30, 2023. The number of employees increased by 128 or 32.24% compared to the previous year.
Employees
525
Change (1Y)
128
Growth (1Y)
32.24%
Revenue / Employee
$37,425
Profits / Employee
-$1,025,973
Market Cap
2.48B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Guardant Health | 1,779 |
| Amphastar Pharmaceuticals | 1,761 |
| Inari Medical | 1,300 |
| Twist Bioscience | 919 |
| Veracyte | 815 |
| GoodRx Holdings | 694 |
| Agios Pharmaceuticals | 386 |
| Catalyst Pharmaceuticals | 167 |
ARWR News
- 10 days ago - Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Business Wire
- 4 weeks ago - Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity - Business Wire
- 6 weeks ago - Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran - Business Wire
- 7 weeks ago - Arrowhead Pharmaceuticals Stock Climbs on Plans To Seek FDA Approval for New Drug - Investopedia
- 7 weeks ago - Arrowhead Pharmaceuticals Presents New Pivotal Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome - Business Wire
- 2 months ago - Arrowhead Pharmaceuticals to Present New Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome - Business Wire
- 2 months ago - Arrowhead Pharmaceuticals, Inc. (ARWR) 2024 Summer Series R&D Webinar: Obesity/Metabolic - ARO-INHBE Conference (Transcript) - Seeking Alpha
- 2 months ago - Arrowhead Pharmaceuticals to Advance Two New RNAi-Based Obesity Candidates, ARO-INHBE and ARO-ALK7, Into Clinical Studies - Business Wire